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Abstract

This study tested the effectiveness of special
~---

packaging in increasing the medication compliance of
hypertensive patients in the outpatient clinic at San
Joaquin General Hospital.

Seventy patients were randomly

assigned to an experimental and control group.

After a 6

week treatment period, the mean compliance estimates for the
experimental and control groups (xl

=

68.59%, x2

=

48.67%)

were compared and found to be significantly different (t
2.46, df

=

33, p

< .05).

=

In addition, a statistically

significant negative correlation was found between
compliance and blood pressure (r = -0.51, p

~

.01).
~-

-
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Medication compliance, "the extent to which the
patient's behavior coincides with the clinical prescription"
(Fletcher, Pappius, & Harper, 1979, p. 635), is the crucial
link between the doctor's prescription and the healing
~-

process.

If patients ingest a reduced amount of the

prescribed medication the treatment goal may either not be
achieved or may be achieved more slowly (Kaplan, 1980).
Overdosing on medication is also undesirable since "many
medications carry greater risks from overdosage than
underdosage" (Rudd, 1980, p. 866).

While underconsumption

of medication has received more attention in the compliance
literature, overconsumption of medication has been estimated
to account for 65% of the problems in medication compliance
which come to a physician's attention (Swinyard, 1980) •
Thus, in any discussion on medication compliance it is
useful to reiterate· that both underdosing and overdosing are
to be viewed as a deficit in compliance.
This paper on medication compliance will first present
a brief literature review on the subject.

A proposed

experiment designed to test the effectiveness of special
medication packaging on increasing medication compliance in
hypertensive patients follows.

Magnitude of Noncompliance
Estimates of how many people are noncompliant range
from 11% to 93% (Shope, 1981) with 50% considered typical
(Sackett & Snow, 1979, Chap. 2).

The wide variability in

;j
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the estimates is caused in part by the different operational
definitions used for compliance (which vary based on the
percentage of compliance necessary for a particular
medication to work in a particular disease).

For example,

in studies on hypertension, patients are classified as
compliant when 80% of their pill taking behavior coincides
with the doctor's advice.
-

However, in the case of diabetes,

-

administration of insulin must concur 95% of the time with
the prescription for the blood sugar level to remain under
control.

Other factors which are responsible for the

variability in compliance estimates include the measures of
compliance used (e.g., self report, pill count, laboratory
tests) and conceptual problems with respect to setting the
cut off point between compliance and noncompliance.

For

example, when a physician prescribes the minimum dosage
required for therapeutic effects to occur, a high degree of
medication compliance is more important for the underdosing
patient than when the physician prescribes more liberally.

Complications of Noncompliance

----

~

Medication noncompliance can not only thwart the health
benefits achieved by accurately following a proper
medication prescription, but can also lead to inappropriate
medication or surgical recommendations and unnecessary
testing by physicians who think their treatment
recommendations are not working.

In addition, in the case

of antibiotics, insufficient use may lead to the development

4

of a strain of organisms which is resistant to the
antibiotic (Matter, Markello, & Yaffe, 1974).

Measures of Compliance

~-

Direct Measures
Analysis of body fluids is the most direct and perhaps
the most accurate way to measure compliance.

Even so, there

~-

are problems with this method (Gordis, 1979, Chap. 3).
First, there are technical problems with respect to a test's
sensitivity and specificity to the presence of the relevant
medication, its metabolite, or a marker (an inert substance
added to the medication specifically for the detection of
compliance).

The test may either not be sensitive to or may

not pick up the presence of the compliance indicator, or it
may lack specificity to the compliance indicator and give a
false positive.

Second, in carrying out a test, it is

important to know the absorption and excretion pattern of
I

the drug in question so that the test is conducted during
the critical time for compliance detection.
Body fluids studied to date for use in compliance
detection include blood, urine, saliva, sweat, semen, and
tears (Litt & Cusky, 1980).

While blood is useful in the

detection of medication compliance for anticonvulsants,
salicylates (e.g., aspirin), digoxin, and theophyllin (for
asthma), its use is limited because of the necessity to use
invasive venipuncture techniques which are painful, time
consuming, require the presence of the patient in the

5

doctor's office, and carry the possibility of introducing an
infection.

For these reasons increasing attention has been

paid to the alternative body fluids such as urine and
saliva.
Because of the high cost of quantitative analysis of
body fluids qualitative analyses have become popular.

For

example, mefenamic and flufenamic acid (to treat arthritis),
and riboflavin (a vitamin marker) fluoeresce when present in
urine exposed to ultraviolet light.

While the use of six

mg. of riboflavin as a marker added to each capsule of
medication seems promising, Scoutter and Kennedy (1974)
caution against its indiscriminate use.

First, false

positives may be obtained in persons who take multivitamins.
Second, testing for the presence of a marker does not
indicate the degree of medication compliance.

Third,

Scoutter and Kennedy point out that a noncomplying patient
may happen to take medication right before the body fluid
collection while a usually compliant patient may forget to
do so.

In addition, riboflavin is so readily absorbed and

excreted by the body that if riboflavin is to be detected in
the urine, the urine should be inspected within two to three
hours after the riboflavin is ingested.

Finally, riboflavin

can change the bioavailability of the medication to which it
is added.

Thus, many pharmacists advise against the use of

riboflavin as a marker.
Indirect Measures
The most commonly used indirect measures of compliance
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are pill counts, self reports, outcome assessments, and
physician estimates.

When combined, these measures are

thought to provide as much information as the more direct
measures (Litt & Cusky, 1980).
Pill count.

The pill count measure of compliance

involves the comparison between the number of pills
remaining in the patient's bottle and the number of pills
that should have remained.

Compliance is reported as the

number of pills removed during a specific time period
divided by the number of pills prescribed for that time
period times 100%.

Problems encountered with this approach

include pharmacist's errors in the filling of the
prescription (Monson & Bond, 1978), underdosing patients
throwing away pills in anticipation of the pill count, and
patients forgetting to make their medication containers
available for the pill count.

Studies which have

investigated the accuracy of pill counts indicate that pill
counts overestimate medication compliance by as much as 10%
(Bergman & Werner, 1963; Roth, Carson & Hsi, 1970).
Self report.

Several investigators have compared self

reports with pill counts and urine tests.

Feinstein, Wood,

Epstein, Taranta, Simpson, and Turskey (cited in Gordis,
1979, Chap. 3) compared interview and pill count estimates
of compliance in penicillin prophylaxis treatment (to
prevent rheumatic fever).

Although both measures had high

agreement with respect to classifying patients into the poor
compliance groups, there were marked differences in their
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classification of patients into good and questionable
compliance groups.

The interview method overestimated the

number of patients classified as having good compliance by
18%.

Chaves (cited in Gordis, 1979, Chap. 3) found negative

urine tests in 27% of the patients who said they took their
pills.

In 1970, Rickels and Briscoe compared 675 self

reports with pill counts and again found that self reports
overestimated compliance.

The discrepancy between self

reports and pill counts was greatest for subjects who were
only slightly noncompliant.

Sheiner, Rosenberg, Marate, and

Peck (1974) found that average outpatients took only 72% of
the digitalis tablets they reported they had taken.
The advantages of using self report include (a) it is
cheap, (b) those who admit noncompliance rarely lie, (c)

if

the only purpose of the interview is to identify
~any

noncompliance,

will be identified, and (d) patients who

admit to their noncompliance during an interview respond
best to interventions (Litt & Cusky, 1980).
Outcome Assessments.

While it is natural to assume

that compliance to a properly prescribed drug therapy will

-~-

~

result in a positive outcome, there are many variables
besides the drug therapy which may affect the outcome (e.g.,
reassurance, stress, sleep, weather, physical health,
strength of virus or bacteria, and severity of illness, to
name a few).

Therefore, compliant patients may sometimes

fail to improve promptly while noncompliant patients may
improve anyway.

This has been demonstrated by Lowenthat,

8

Briggs, Mutterperl, Adelman, & Creditor (1976).

Only 44% of

the compliant patients achieved controlled blood pressure
whereas 56% of the compliant patients did not.

Furthermore,

16% of the noncompliant patients achieved blood pressure
control despite their lack of compliance.
Gordis (1979) also notes that "the effect of
noncompliance is highly dependent upon how closely the
prescribed dosage approximates the minimum dosage required
for optimal therapeutic effect •••• If for example the
prescribed dosage substantially exceeds the mimimum effect
dosage, low compliance may not reduce effectiveness at all"
(p. 34).

Physician estimates of compliance.

While it may seem

logical to assume that experienced physicians would be adept
at estimating their own patients' compliance, studies have
shown that this assumption is false.

Charney, Bynum,

Eldridge, Frank, MacWhinney, McNabb, Scheiner, Sumpter, and
Iker (1967) showed that pediatricians' predictions of
complia.nce were no better than chance.

Caron and Roth

(1968) found that 46% of physicians overestimate compliance.
They noted that the senior physicians were no better at
predicting than the junior physicians who in turn were no
better than the residents.

Davis (1966) found that medical

students were indeed better at predicting noncompliance than
attending physicians.

~

-
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Determinants of Compliance
Features of the disease
Disease characteristics are considered unimportant as
determinants in compliance (Haynes, 1979, Chap. 4).

Less

~-

than half of the disease factor studies that Haynes, Taylor

& Sackett (1981) reviewed found significant correlations
between disease factors and compliance level.
exceptions to these are:

The

(a) that psychiatric patients tend

to be low compliers, (b) the more numerous the symptoms
possibly the lower the compliance, and (c) increased
disability may be accompanied by increased compliance.
Clinical Setting and the Referral Process
Because attendance at the physician's office and
medication compliance are related, it is helful to look at
features of the referral process and clinical setting which
help the patients to keep their physician's appointments.
Although there is lack of research in both areas, several
helpful factors have been determined; (a)

the longer the

time between the referral and the appointment, the lower the
chances are that the patient will keep the appointment
(Haynes, 1979, Chap. 4), (b) Hoening and Ragg (cited in
Haynes, 1979, Chap. 4) found that patients referred to a
psychiatric clinic were more likely to keep their
appointment if the referral was to a specific physician, and
(c) decreasing the waiting time in the clinic may increase
clinic attendance (Rockart & Hoffman, 1969).

10
Features of the Regimen

~--

Getting patients to keep their clinic appointments will
not necessarily increase medication compliance.

There are

several features of the treatment regimen which also affect
medication compliance {Haynes, 1979, Chap. 4).

They are as

follows;
{1) Duration of treatment.

Numerous studies have shown

that the duration of treatment is accompanied by a
concomitant decrease in medication compliance {Haynes, 1979,
Chap. 4).
{2) Complexity.

Studies almost unanimously indicate

that the greater the number of medications prescribed the
lower the compliance {Haynes, 1979, Chap. 4).

However, the

influence of the frequency of medication in the medication
~--

regimen is not as well understood.

Some studies have

indicated that as the frequency of taking medication
increases from once a day to four times a day, the
medication compliance decreases.

Other studies have failed

to support this observation {Haynes, 1979, Chap. 4).
{3) Side effects.

Intuitively speaking, I would expect

that the greater the number of side effects of taking a drug
the lower the compliance would be.

While some studies which

cite data for psychiatric patients support this contention,
the majority of studies have provided evidence which refute
it {Haynes, 1979, Chap. 4).

For example when patients have

been asked to list their reasons for noncompliance, side
effects are mentioned only 5% to 10% of the time, and even

--
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then they are mentioned towards the bottom of the list.
This finding indicates that while side effects may be
important when they occur, they are not the most common
cause of noncompliance.
~-

(4) Cost.

Most studies have demonstrated a negative

relation between cost and compliance, although a few have
found no correlation or a positive one (Haynes, 1979,
Chap. 4) •
(5) Dispensing.

Haynes (1979, Chap. 4) describes a

controlled study which was carried out on the effects of the
safety lock on pill containers with respect to compliance.
The data showed that the safety lock significantly reduced
medication compliance.

Many who did comply reported that

they had removed the safety container top.
Mattar, Markello, and Yaffe (1975) found that community
pharmacists, when filling prescriptions, dispensed less
medication than was prescribed on 15% of all prescriptions
for an antibiotic for otitis media.
Patient characteristics
(1) Demographics.

Studies have generally shown that

knowledge of a patient's demographic characteristics does
not help to predict medication compliance (Mathew & Hingson,
1978).
(2) Knowledge.

While knowledge about a medication

regimen and disease is helpful, it is not in and of itself
sufficient to insure compliance (Bergman & Werner,

1963~

Sackett, Haynes, Hackett, Taylor, Gibson, Roberts, &
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Johnson, 1975).

Sackett et al. (1975) conducted a study on

steel workers with newly discovered hypertension in a
Canadian factory.

The hypertensive workers were divided

into a group which received special instruction concerning
hypertension and its treatment and a group which did not
receive any special instruction.

While the group members

which received special instruction concerning hypertension
scored higher on a quiz testing knowledge about
hypertension, they were not found to be more compliant than
the group receiving no special instruction.
(3) Health belief model.

According to the health

belief model the probability patients will follow medical
advice is a function of the patients' perceived
susceptibility to the disease, the perceived severity of the
~-

---

disease, and the perceived benefits and barriers related to
compliance.

The model also includes other variables (such

as motivation, physician-patient interaction,
characteristics of the regimen, etc.) as influential on
compliance (Hershey, Morton, Davis, & Reichgott, 1980).
Several studies testing the model have shown positive

--

correlations up to .5 and .6 between the patients' health
beliefs and feelings and their compliance (Becker, Maiman,
Kirscht, Haefner, Drachman, & Taylor, 1979, Chap. 6).

The

correlations tend to be higher when the health beliefs are
compared with concurrent rather than subsequent medication
compliance, which may suggest a bidirectional relationship
between the two variables.

-

That is, patients' beliefs may

13
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affect their medication compliance and compliance may

~

influence beliefs.
(4) Locus of control.

Locus of control refers to the

way a person views the events which occur in his/her life.
Persons with an external locus of control believe that
whatever happens to them is due to chance, luck, fate, or
some outside power.

On the other hand, persons with an

internal locus of control believe they are in control of
what happens (Duke & Cohen, 1975).

Several studies have

supported the contention that internal locus of control is
significantly related to compliance (Hershey, et al., 1980;
Duke, et al., 1975, Becker, et al., 1979) although more
studies need to be conducted.
(5) Disease denial and rationalization.

Podell and

Gary (1976) suggest that denial or rationalization of a
medical condition is related to medication noncompliance in
hypertensive patients.

In their study half of the patients

who failed to take their medication or go to their physician
appointments presented illogical excuses such as "I knew my
blood pressure was high so I did not keep my appointment."
Features of the Doctor-Patient Interaction
Several features of the doctor-patient relationship
have been studied, some of which have been shown to have a
significant impact on patient compliance.

Patients' overall

satisfaction with their care has been repeatedly
demonstrated to have a positive relation to compliance (Daly

& Hulka, 1975).

When patients' expectations are met, they

;; ___ _
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are more likely to comply (Shope, 1981).

As the level of

~=---

medication supervision increases medication compliance
increases (Haynes, 1979, Chap. 8).

Other variables which

may be related to compliance include the patient's belief in
~-

the physician's ability and the patient's perception of the
physician as friendly (Shope, 1981).
Strategies For Improving Patient Compliance
~here

-

have been several strategies proposed to improve

patient compliance.

Before initiating an attempt to improve

medication compliance however, Albert Jensen (1979) suggests
that the experimenter be able to verify that the following
guidelines have been met;

(a) the physician's diagnosis is

correct, (b) the drug therapy will do more good than harm to
the patient, and (c) the patient is an informed and willing
participant.
Patient Education
(1) Disease and treatment.

Theoretically one would

hypothesize that patient education would increase medication
compliance.

Research has shown, however, that patient

education is not a sufficient condition for medication
compliance to occur (Haynes, 1979, Chap. 8).
(2) Medication regimen.

Patient errors in medication

can be subdivided into (a) faulty comprehension of
medication regimen accompanied by medication errors, and (b)
good comprehension of medication regimen accompanied by
medication errors.

Because studies indicate that medication

errors are frequently accompanied by faulty comprehension of
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the treatment regimen, it would behoove the health care
provider to carefully explain the treatment regimen itself,

l-!--

~

to perhaps provide written instructions of the schedule
(Podell, et al., 1976; Blackwell, 1979), and to ask patients
~--

to explain the treatment as they understand it to validate
their comprehension of the treatment.
Drug Regimen
Another way to decrease faulty comprehension is to
simplify the medication itself by reducing the number of
different medications used and reducing the frequency of the
medication administrations.

Studies which have compared the

efficacy of the different dose frequencies have all
indicated that the less frequent regimens are as effective
as the more frequent regimens (Blackv1ell, 1979).

However,
~

--

recent work in juvenile onset diabetes mellitus indicates
that frequent administration of insulin might be
advantageous due to its superior control of blood sugar
levels (Davidson, 1981).
While it is a common belief that the larger, less
;:;:=

frequent doses of medication are accompanied by more side
effects, this has not been supported in the literature to
date (Blackwell, 1979, Chap. 9).

Caution and discrimination

should nonetheless be observed in prescribing larger doses,
and side effects should be monitored.
Tailoring
Although tailoring has not been studied as an effective
variable in and of itself, it intuitively would seem that

;-:---
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tailoring a medication to a patient's own schedule
would increase compliance.

For example, Podell and Gary

(1976) suggest scheduling the ingestion of a diuretic during
the time of day the patient will have a bathroom at his
disposal.

Norell (1979) found that medication compliance

was greatly improved in subjects who were given an education
and medication tailoring program.
Parenteral Drug Administration
Numerous studies have shown that whenever injections
can be given by the health care provider, patient compliance
increases (Haynes, 1979, Chap. 8).

The low rate of

compliance found in diabetics who are prescribed daily
injections of insulin underscores the importance of the
health care provider's role in the drug administration
~

--

rather than the injection itself.
Extended Supervision
The concept of extended supervision involves such
things as frequent clinic visits, making home visits, using
outreach clinics to reach those who might otherwise fail to
go to the doctor, and adding an extra person to the health

-

~

care team to supervise the patients' use of their
medications.
Many studies demonstrate the effectiveness that
extended supervision has on medication compliance, though it
is difficult to separate the effects of supervision from
patient education and counseling (Haynes, 1979, Chap. 8).
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Patient Involvement and Behavior Modification
Such behavior modification techniques as (a) positive
reinforcement, (b) negative reinforcement (Azrin & Podell,
1969), (c) security-deposit contingency contracts, (d) self
monitoring (Epstein & Masek, 1978), and (e) contingency
management (Lowe & Lutzker, 1979) have been used
successfully to increase compliance.

Haynes (1979, Chap. 8)

-

-~

comments that while many of these techniques would be
difficult and expensive to implement in a private office,
they do demonstrate the effectiveness of the principle
involved.
Attendance at the doctor's office is positively
correlated with medication compliance (Haynes, 1979,
Chap. 8).

To encourage clinic/office attendance, such
~

procedures as calling patients or sending them reminders of
their scheduled appointments have been effective.

In

addition, reducing the time patients have to wait in the
office before they see the physician has also been shown to
increase medication compliance (Rockart et. al., 1969).
Medicine Packaging
Special medication packaging works as a discriminative
stimulus or cue for appropriate pill taking behavior.

Such

packages are designed so that patients can see when each
pill should be taken and if a particular pill has been
taken.

One of the most attractive features of this approach

is that it is time efficient, i.e. the packaging effects a
maximal response to medication compliance with a minimal

-
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intervention.

This approach works around such difficult

F.==

h ---
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variables to control as physician-patient interaction and
relationship, medication regimen, and patients' health
beliefs.

_j

For these reasons special medication packaging
:::::;_-

~-

will be used in the proposed study.

Several studies have

been conducted to determine the effectiveness of special
pill containers and daily reminders (Demetral, Gipson,
Irwin, Anderson, & Catania, 1981; Eshelman, & Fitsloff,
1976; Gazzar, 1978; Linkewich, Catalano, & Flack, 1973;
Rehder, McCoy, Blackwell, Whitehead, & Robinson, 1980).

The

effectiveness of such special pill containers has been
repeatedly demonstrated with psychiatric medications (see
Weber, Demetral, Anderson, Gipson, & Catania, 1978, for more
information), but research conducted with other disease
populations has been inconclusive.
For example, the beneficial treatment effects of the
special medication packaging were clearly demonstrated in
the short term study conducted by Linkewich, et al. (1973)
on penicillin compliance although a second treatment
variable, an instruction card, was added to the package.
This instruction card could have interacted with the special
packaging to enhance its effectiveness.
Eshelman et al. conducted a study with hypertensive
patients in 1976.

In this study the special medication

packaging alone was compared to a control group who received
their medication in regular vials.
somewhat confusing.

The results were

While a urine assay indicated that
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medication compliance had increased, the pill count showed
very little change.
of what occurred.

There are several possible explanations
Most likely (a) the diuretic measured in

the urine assay, chlorthalidone, gave an overestimate of
medication compliance due to its long half life, (b) several
subjects given the special treatment package continued to
take their medication out of the vials at least part of the
time.

If this occurred, medication compliance as measured

by the pill count of the special package was underestimated.
Thus, an average or summation of the two estimates would
probably have yielded the most accurate estimate.

When I

averaged the results, 65% of the patients receiving their
medication in the bottles were compliant versus 78% of the
patients receiving their medication in the special
packaging.

However, when the data was submitted to a chi

square analysis the difference between the two group's
proportions of compliant patients was not statistically
significant.

Thus, the special medication packaging was ·not

shown to increase medication compliance in this case.
Rehder et al.

(1980) conducted a three month study on

-

~

hypertensive patients.

One hundred subjects were assigned

randomly to one of four groups:

(a) the control group, (b)

the disease and medication counseling group, (c) special
medication container group, and (d) the special medication
container and counseling group.
a pill count.

Compliance was measured by

A problem with the study was that only 64% of

the patients who kept their pharmacy appointments brought in
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their pill containers for a pill count.

It would seem

R=

~

likely that the patients who brought their pill containers
in would tend to be the most compliant in taking their
medication.

R

~-=--=:o_

_j

It is not surprising, then, that the medication
~--
~---

compliance estimate obtained by the pill count was very high
across all four treatment groups (greater than 85%), and
that there were no significant differences between treatment
-~

groups.

However, when the percentage of patients who had

greater than 95% medication compliance was compiled for each
group, the counseling and special medication container group
and the special medication container alone group had a
significantly greater proportion of 95% compliance patients
than either the counseling alone or control groups.

In this

study the subjects' blood pressures in each treatment group
were also noted.

That blood pressure changes did not

reflect the differences in medication compliance is not
surprising since once a patient is over 80% compliant in the
ingestion of antihypertensive medication, other variables
are considered to be more important in lowering blood
pressure (such as salt intake and amount of antihypertensive
medication prescribed).
Thus, while the effectiveness of the special medication
packaging has been demonstrated with psychiatric
medications, its effectiveness with nonpsychiatric
populations needs more empirical support.

A nonpsychiatric

population of particular interest is the hypertensive
population.
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Hypertension
Hypertension (high blood pressure) is a serious
disorder which affects 15% to 25% of adults in the United
States (Williams, Jagger, & Braunwald, 1980).

There are

four plausible end-organ effects associated with
hypertension if left untreated:

(a) kidney failure due to

glomerularsclerosis (scarring of the glomerula in the
kidneys which filter poisons out of the blood), (b) heart
failure due to left ventricular hypertrophy, (c) cerebral
hemorrhage, (d) atherosclerosis which may lead to a
myocardial infarction or a stroke.
Medications used to treat hypertension are divided into
three classes or "steps", with each step associated with
increasing risks for side effects.

Step I medications

include diuretics and are the treatment of choice of a
person with newly discovered hypertension or borderline
hypertension.

If a step I treatment does not lower the

blood pressure enough, step II drugs such as beta blockers
and central acting drugs are added.

Finally, if neither

step I or step I and step II drugs used together are
sufficient, a step III treatment, vasodilators, may be tried
in addition to the step I and step II drugs.

Vasodilators

reduce blood pressure by acting directly on the constricted
vessels thereby expanding them so as to reduce the pressure.
While properly prescribed and taken antihypertensive
drug therapy is usually effective in reducing blood
pressure, noncompliance is a common problem.

For example,
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in Sackett's 1975 study conducted on hypertensive steel
workers he and his associates found that only 48% of the
patients in the control group were compliant in taking their
medications.

Only 53% of patients receiving extensive

training on hypertension and its treatment were classified
as compliant at the end of the six month experiment.
Sackett et al. concluded that instructional strategies
''fri.volving more direct attempts of behavior modification"
were more likely to be successful (p. 1207).

Lowenthal,

Briggs, Mutterperl, Adelman, and Creditor (1976) found that
50% of the patients in their study were compliant.
Explanations of low compliance in hypertensives include
(a) hypertensive patients are usually asymptomatic and thus
""
~-

have difficulty believing that they are "sick" and need to
::;

take medication, (b) the medication is expensive, (c) the
medication has potential side effects which range from
dizziness, weakness, and headaches, to depression, potassium
depletion, and exacerbation of asthma and heart failure
(Williams, Jagger, & Braumwald, 1980), (d) the medication
does not cure the cause of hypertension - thus patients are
put on a long term drug regimen indefinitely, (e) patients
on more complex drug regimen get confused with respect to
when to take each medication, (f) patients forget if they
have taken their medications.

Each of these explanations

for noncompliance has been discussed earlier in the paper
(see pp. 8-12).

--
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What remained to be shown is that special medication
packaging could indeed increase medication compliance in
hypertensive patients.

The special medication packaging

works as a discriminative stimulus or cue for appropriate
q--

pill taking behavior.

To this end the packages are designed

so that the patient can see when each pill should be taken
and if a particular pill has been taken.

Because of its

form the special packaging addresses two of the previously
mentioned explanations for medication noncompliance - when
to take the pills and if a particular pill has or has not
been taken.
To adequately demonstrate the effectiveness of the
special medication packaging, a study was carried out that
controlled variables which might either challenge the
;:; - ----=-

study's internal or construct validity or otherwise make the
results of the experiment hard to evaluate.

The following

suggestions were integral to the study described throughout
the rest of the paper:
(1)

Select a group of hypertensive patients who are

judged to be capable of self administration of medication.
(2)

Where applicable, prescribe hydrochlorothiazide

(HCTZ) or dyazide to patients who need to take a diuretic
because the thiazides are easily detected in the urine.
Hydrochlorothiazide is preferred over chlorthalidone because
it has a shorter half life (2.5 hours versus 44 hours).
Thus detection of its presence in the urine indicates that
the medication was ingested within the previous 24 hour
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period.

On the other hand, the presence of chlorthalidone

indicates that medication has been ingested within the past
48 to 72 hours.

p_
H---

q~--

Because the antihypertensive medication

regimen is a daily one, hydrochlorothiazide gives a more
~-

accurate estimate of medication compliance (Benet & Sheiner,
1980}.

Urine specimens should be collected within four

hours after the ingestion of the medication to insure the
detection of the medication's presence.
(3}

Offer the special treatment package alone to an

experimental treatment group and compare the medication
compliance to a control group whose drugs are dispensed in
regular pharmceutic vials.
(4}

Use nonreactive routine tests to estimate

medication compliance (e.g. urine samples, blood pressures}
~

in order to avoid such reactive patient responses as "the
guinea pig effect" (Webb, Campbell, Schwartz, & Grove, 1981,
p. 49} where patients change their usual behavior (such as
medication compliance} due to their awareness of being
observed.

By using measures that the patients are familiar

with the guinea pig effect can be avoided.
(5}

To increase the probability that the patients

assigned to the special medication packaging group
discontinue using their old pills in the vials, several
months before the experiment begins the physicians
participating in the study should be asked to prescribe only
the number of pills that the patients estimate they need in
order to continue taking their medication until the next
clinic visit.

--
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Subjects
'

The 70 patients who qualified to participate in the
study were referred by three hospital resident physicians
and one staff physician.
(1)

Criteria for selection included:

an untreated diastolic blood pressure greater than

90 mm Hg or systolic blood pressure greater than 145 mm Hg.

12) ·
(3)

~ap~bllity

to administer medication to one's self.

exclusive use of the hospital pharmacy to fill

antihypertensive medication prescriptions.
(4)

being a patient of a physician who agreed to

follow the guidelines of our study as listed below.
Treatment Conditions
The 70 patients were randomly assigned to the two
treatment groups of the posttest-only control group design:
(1)

Group I, which received the special pill

containers and a posttest.
(2)

Group II, which received the regular pill

containers and a posttest.
~- _:__

Patients were assigned so that each group would have
approximately the same number of patients receiving Step I
treatment (only diuretics), Step I & Step II treatments, and
Step I, II, and III treatments.

All patients were seen by

their doctor on at least one occasion prior to the beginning
of the study.

After repeated rescheduling of clinic

appointments we were able to get only 48 patients to come to

~
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the first clinic appointment of the study.

Of these 48,

72.9% or 35 came to the second scheduled clinic appointment.

td_·
r
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The second clinic visit was not rescheduled if missed
because the number of pills prescribed during the first

F.--

visit matched the number of days between the scheduled
appointments.

Thus, pill counts and urine assays would

necessarily be affected by an extension between the first
-

and second clinic visits.
The demographic characteristics of the 35 patients who
remained in the study are similar to those who dropped out
(see Table I for a comparison).

About a third of the

patients were white, a third black, and a third were of
Mexican or Oriental descent.

About a third of the patients

were married, about a fourth were widowed, and the remaining
patients were single, separated, or divorced.

Only 2 of the

35 patients' expenses were covered by a third party (i.e.
insurance).

Nine patients were classified as private (i.e.

having no funding other than their own) and 24 patients'
medical expenses were covered by government sources (i.e.
Medi-Cal and Medi-Care).

The patients who remained in the

study did not differ significantly with respect to
demographic characteristics from the subjects who dropped
out.
Of the 35 patients lost in the study it is known that
one was hospitalized for a myocardial infarction, another
was hospitalized for coronary bypass surgery, two moved out
of town, three were misrouted to other physicians, two

=-----t-~
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Table I. Summary of Demographic Characteristics of Study Subjects
versus Drop Out Subjects and Experimental versus Control Subjects
Demographic
Characteristics

Study
Subjects
N=35

Drop Out
Subjects
N=35

Experimental
Subjects
N=l4

Control
Subjects
N=21

59.77

54,80

58.79

60.43

14.53

13.33

15.03

14.53

White

11

14

3

8

Mexican
Black

5
14

8
12

3

2

7

7

Oriental

5

1

1

4

4

4

2

2

14

18

7

7

Widow

9

5

4

5

Separated

2

4

0

2

Divorced

6

4

1

5

Payment Medicare

3

1

2

1

11

6

4

7

Private

9

11

3

6

Medi-cal

10

15

4

6

2

2

1

1

18

15

8

10

Formoso

4

4

2

2

Vaughan

6

12

2

4

Renal

7

4

2

5

30

21

12

18

Lathrop

0

1

0

0

French Camp

0

3

0

0

Galt

0

1

0

0

Linden
Tracy

1
1

0
1

1

1

0
0

Manteca

2

4

0

2

Lodi

1

4

0

1

Age

Mean

Standard Deviation
Race

Harital Single
Status
Married

Medicare/
Medi-cal

3rd Party
Doctor

City

Young

Stockton

~

~--
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patients became angry and left before seeing their physician
after waiting in the clinic office for over an hour, and one

g--~~

~~

experimental patient was mistakenly given her medication in
vials at the pharmacy.
Of the 35 subjects who were followed throughout the
study, 14 were in the experimental group and 21 were in the
control group.

As can be seen in Table I, the demographic

characteristics are approximately equivalent between the
experimental and control groups.
Special Pill Containers
The special pill containers were equivalent to the
Medi-Dose containers used by Demetral et. al., (1981) in
their study on medication compliance.

The prescribed anti-

hypertensive pills were placed individually in plastic
compartments on medication cards clearly labelled for the
time of day each pill should be taken.

There was a new

medication card or container for each day of the regimen,
and these pill containers were given to patients in the
correct order of their intended use.

It should be noted

here that special medication packaging has been described as
difficult to open (Eshelman & Fitzloff, 1976).

Thus the

special medication packages probably did not enjoy an unfair
advantage over the safety-cap prescription vials with
respect to the ease in which the containers were opened.
Procedure
Physician guidelines.
(1)

The patients' second clinic appointment was six

=---"
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weeks after the first appointment.
(2)

Medication prescriptions covered the six week

interval between clinic visits.
(3)

If the patient was on a beta blocker, the

patient's pulse was taken at the final clinic appointment.
(4)

Urine samples were collected on the day of the

second clinic visit.
(5)

Special medication packaging patients were told

that their antihypertensive medication would be dispensed in
different containers and that the patients should
temporarily discontinue their "old" medication.
(6)

All patients were reminded to bring in their

medication on their next scheduled visit.

The reminder came

in the form of telling the patients not to forget and giving
the patients a written reminder with the date of the next
scheduled visit.

Pharmacist guidelines.

Patients in the control group

received their medication as usual in the safety-cap
prescription vials from the hospital pharmacists.

As is

customary, the hospital pharmacists briefly explained the
medication regimen (i.e. read the vial label).

Patients in

the special medication container group received their
medication at the hospital pharmacy in the special
medication packages with the same explanation of the
medication regimen (i.e. read the label).

In addition, the

~
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pharmacists briefly explained how to use the packaging.
In order for the experiment to have high internal validity

~-

-

~~~~--

(which means that the experimental results are due to the
manipulation of the treatment variables), both the special
packaging group and the control group received the same
treatment in all respects as much as possible, except for
the special packaging.

Thus the pharmacists gave the

control group the same amount of time and attention as they
gave to the special packaging group.
The pharmacists were requested to be brief and
nonjudgmental in their explanations concerning the new
packages and to explain that the hospital was just trying
them out.

Giving additional information was avoided.

Nurse guidelines.

The nurse completed her routine duty

of taking each patient's blood pressure before the patient
saw the doctor.

In addition, the nurse requested the

patients to provide her with a urine sample while they were
waiting in the clinic to see the doctor.
Dependent Measures of Compliance

;;; ____ __:_
fi

Medication compliance was estimated by the following
measures:
( 1)

presence of hydrochlorothiazide in the urine

( 2)

resting pulse at clinic visits for patients taking

beta blockers
(3)

the blood pressure reading at clinic visits

(4)

the pill count at each clinic visit

-
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(5)

the blood pressure reading at any emergency room

~

. .·
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visit during the study period
A special attempt was made to use nonreactive
measures as recommended by Webb, Campbell, Schwartz, and
Grove (1981) so that the estimates of compliance would be
more accurate.

The raw score obtained on each measure for

each subject was assigned the number of points suggested by
a table of weighted scores which was constructed before the
study began (see Appendix A for the listing).

One dependent

measure was dichotomous (the presence or absence of
medication in the urine) while other measures estimated
several levels of compliance.

Each subject was assigned a

percentage compliance score by adding up the total number of
points earned and dividing that sum by the total number of
points possible for that individual.

Once each subject was

assigned a score, the mean percentage compliance score and
standard deviation for all the subjects was calculated and
the mean percentage compliance scores for the special
packaging treatment group and the control group were

~
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compared with a t-test.

In addition the means for each

individual compliance measure were compared using the raw
scores when possible.
Detection of medication in the urine.

Lowenthal,

Briggs, Mutterperl, Adelman, and Creditor (1976) describe a
test for the detection of thiazide diuretics (such as
hydrochlorothiazide and dazide) in the urine which yields
qualitative results (i.e. the presence or absence of the

~~----~
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drug rather than quantity).

Urine specimens of patients who

are prescribed thiazides were subjected to this test and
were scored as follows:

r-

~
-
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~~~-.-~

for the detection of any amount of

thiazide in the urine, 10 points were assigned.
Resting pulse.

If blood pressure control is not

achieved by diuretics alone, beta blockers (a step II
treatment) may be added.

The beta are receptors of the beta

part of the sympathetic nervous system.
receptors located in the heart.

There are beta

When these are stimulated,

there is an increase in heart rate and ultimately an
increase in the blood pressure.

The role of the beta

blockers, then, is to block the beta receptors from
responding to stimulation by the sympathetic nervous system
and thus slow down the heart rate and decrease the blood
pressure.
study.

The beta blocker propranolol was used in this

The resting pulse of patients taking beta blockers·

was measured at the second clinic visit.

If it was less

than 80 beats per minute, the patient received 8 points.
it was between 80 and 90, 4 points was assigned.

If

If it was

~

~

greater than 90, no points were assigned.
Blood pressure.

The blood pressure was also measured

at each clinic visit as an indication of the patients'
medication compliance.

While this measure, as discussed

earlier, is far from perfect, successful blood pressure
control is indicative of medication compliance and an
extremely high blood pressure (greater than 110 diastolic or
190 systolic) is indicative of noncompliance.

The scoring
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for this measure can be found in Appendix A.
Pill count.

The pill count measures of compliance

involves the comparison between the number of pills
remaining in the patient's bottle and the number of pills
that should have remained.

Consumption is reported as the

number of pills removed during a time period being measured
divided by the number of pills prescribed for that time
period times 100%.

See Appendix A for scoring.

Emergency room visits.

During the study period we

expected that some of the patients in our group would visit
the emergency room in regards to a minor medical problem.
Since it is routine at the emergency room to have one's
blood pressure measured and recorded upon requesting
treatment, we decided that in the event that some of our
study patients would visit the emergency room we would
obtain and use their blood pressure as a nonreactive measure
of compliance.

~ve

believe that the emergency room blood

pressure was more likely to reflect the true degree of
compliance than the clinic blood pressure because

~

~

underconsumers could not easily "prepare" for an emergency
by abruptly taking their medications as they might for a
routine clinic visit.

The scoring of the blood pressure

readings taken at the emergency room was somewhat different
than the clinic blood pressure readings since emergency room
visits by nature are more stressful, and therefore more
likely to elevate blood pressure.
actual scoring.

See Appendix A for the
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The combined measures of compliance indicate that the
experimental group

X=

68.59% was more compliant in taking

medication than the control groupx
33, p <_.OS).

=

48.67% (t = 2.46, df

=

This difference of 20 percentage points is a

42% improvement in score.

Although most individual measures

of compliance suggest that the experimental group was more
compliant than the control group, none of the individual
measures of compliance were able to differentiate the
experimental group from the control group at a statistically
significant level.

The mean values for each of the measures

used are presented in Table II.
Because the purpose of antihypertensive medication is
to lower blood pressure, this measure of compliance was
examined more closely than the other measures.
A statistically significant negative correlation was
found between the combined compliance measures (minus the
blood pressure measure) and the combined systolic and
diastolic blood pressure of all the subjects (r

= -0.51,

E<
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.01).

However, no statistically significant difference was

found between the experimental and control groups' blood
pressure (combined or diastolic) at the end of the six week
treatment interval.
Over the six week treatment interval the experimental
groups' combined blood pressure (Xl

=

232.71, ~2 = 229.07)

dropped an average of 3.64 points per person while the
control group's combined blood pressure reading

(X1

=

Table II.
Summary of Individual and Combined Estimates of Medication Compliance
in the Esperimental and Control Groups
·
Control

Experimental
n

x

s.d.

n

x

s.d.

Individual Measures
Clinic Blood Pressure
combined systolic and diastolic
diastolic
Pulse

(mm Hg)

14

229.07

23.05

21

228.67

28.33

14

83.36

8.59

21

84.57

10.66

7

68.86

8.13

6

75.17

13.24

96.42%

4. 73%

9

81.33%

30.68%

(beats per minute)
(percent of pills taken)

12

(+ denotes detection. of HCTZ)

9

2 samples +

3

123.33

14.27

0

3

75.33

3. 77

0

18.56%

21

Pill count
Urine

(mm Hg)

15

2 samples +

Emergency room blood pressure
systolic
diastolic

(mm Hg)
(mm Hg)

Overall Percent Compliance Estimate
(Combined Heasures)

14

68.59%

48.67%

26.13%

c.u
c.n

1

I
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224.19, X2 = 228.67) increased an average of 4.48 points per
person.

These changes in blood pressure were not found to

be statistically significant at the p

=

.05 level.

~

~
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Discussion
The use of multiple measures of compliance has proved
useful in this study.

While most individual measures of

compliance suggested that the special medication packaging
increased medication compliance, no measure alone
demonstrated a statistically significant difference between
the experimental and control groups.

By combining a variety

of measures we were able to approach the construct of
compliance from several angles and thus obtain a more
accurate estimate of the true compliance rate of each group.
Just as data on individual subjects in an experimental
and control group do not always point to the general pattern
of results, the data we obtained on the individual measures
of compliance varied from the general pattern which emerged
when data from all the measures were summated.

The pill

count provided a maximum estimate of compliance whereas the
urine assay provided a minimal estimate.

This occurred

because each individual measure (just as each individual
patient's data) is subject to error.

The pill count was

likely an overestimate of compliance due to it's reactive
nature (asking the patients to bring the pills in and
providing them with a written reminder).

Other possible

errors include the pharmacist dispensing the prescription as
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requested, the experimenter counting the pills accurately,

t1----=----

and the most compliant patients "remembering" to bring their
pills in.

A different type of error is hypothesized to have

affected the detection of HCTZ in the urine.

In an effort
:..-'--~-

to obtain a nonreactive measure of compliance, patients were
not warned ahead of time that a urine sample would be taken
at the second clinic visit.

Instead, nurses requested the

samples as soon as the patient reported to the clinic on the
day of their second appointment.

However, most patients

voided minutes prior to checking in.

Since the half life of

HCTZ is 2.5 hours, and patients were scheduled to check in
approximately four hours after ingestion, it was important
to obtain the earliest urine sample possible.

Patients who

voided just prior to the clinic visit had probably excreted
most of the medication.

Thus, when the nurses requested

urine samples, there was little medication left to excrete.
Another possible source of error includes the sensitivity of
the HCTZ detection test: The test we used may not have
picked up the presence of HCTZ.
Though blood pressure was negatively correlated with
compliance across all subjects, there was no statistically
significant difference found between the blood pressure
measures or changes in measures in the experimental and
control groups.

Several reasons are postulated:

(1} all subjects had been receiving treatment for
hypertension when the study began (i.e. no newly discovered
patients began with out study).

Therefore, most patients'
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blood pressure in both groups were already under fair
~

-----
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control at the beginning of the study.

~--~"
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(2) factors other than compliance may affect blood pressure
(e.g. appropriateness of drug, the dosage level, and diet).
~--

(3) A period of six weeks may not be of sufficient duration
for the blood pressure to fully respond to the increased
rate of compliance caused by the special packaging.
(4) A sample size of n

=

14 experimental subjects may have

not provided enough power to detect the effect that
increased medication compliance has on blood pressure.
An attempt was made to use nonreactive measures in this
study.

All measures with the exception of the pill count

appeared to meet this goal (no one questioned the reason why
any measure was taken with the exception of the pill count).
When patients were requested to bring their pills to the
second clinic appointment of our study, many asked why.
Several comments indicated that the patients knew why we
wanted them to return with the pills (e.g. "You want to see
if I take my pills, huh?").

Since the pill count was so

~----

e-

reactive it is not surprising that of all the compliance
measures the pill count gave the highest estimates for both
the experimental and control groups.
This study has demonstrated the effectiveness of the
special medication packaging in increasing compliance rates
in hypertensive patients on a short term basis.

New studies

need to be carried out which can demonstrate the
effectiveness of the special medication packaging on a long

~-

~
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term basis.

If the packaging is found effective over a

period of several months, it is probable that statistically

"'~
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~

significant drops in blood pressure in comparison with a
control group will result, thus making the cost of packaging
~--

justifiable.

New populations of subjects (e.g. diabetics,

patients with congestive heart failure; private office and
family practice patients) need to be studied to demonstrate
the effectiveness of the special medication packaging across
different medical conditions and settings.

~
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APPENDIX A
Point system for quantifying the measures of compliance
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Measurement

Points

(1)

Detection of hydrocholorothiazide in the urine

(2)

Blood pressure reading at the clinic visit:
(a)

both systolic less than or equal to

145 and diastolic less than or equal to 90
(b)

10

10

both systolic less than or equal to

170 and diastolic less than or equal to 100,
but either systolic greater than 145 or
diastolic greater than 90 [If both are
equal to maximum value (170, 100), score 0]
(c)

4

either systolic greater than 170 or

diastolic greater than 100 or both equal 170

& 100
(3)

Resting pulse:
(a)

less than 80 per minute

8

(b)

between 80 and 90 per minute

4

(c)
(4)

0

greater than 90 per minute

0

Pill count at clinic visit:
(a)

relfects taking better than 90% of

medication
(b)

relfects taking between 80% and

90% of medication
(c)

10

5

reflects taking less than 80% of

medication

0

;;:: ____ _
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(5)

Blood pressure reading at any emergency room visit:
(a)

=

both systolic less than or equal

to 145 and diastolic less than or equal to 90
(b)

r,_:_ --

15

either systolic greater than 145 or

diastolic greater than 90, but both systolic
less than or equal to 160 and diastolic less
than or equal to 100
(c)

8

either systolic greater than 160 or

diastolic greater than 100 but both systolic
less than or equal to 190 and diastolic less
than or equal to 110
(d)

4

either systolic greater than 190 or

diastolic greater than 110

~-

0

